SELLAS Life Sciences (SLS) announced the European Commission has granted Orphan Drug Designation for SLS009, a highly selective CDK9 inhibitor, for the treatment of acute myeloid leukemia. The company said it remains on track to share further data around SLS009 in the third quarter of the current year.
"This designation along with the recently announced strong preliminary Phase 2 data and previous FDA ODD designation reinforces our continued progress and commitment to developing SLS009 as a potential treatment for AML," said Angelos Stergiou, CEO of SELLAS.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.